Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047082 | 1.00 | — | — | |
| SCHEMBL18019251 | 1.00 | — | — | |
| SCHEMBL29759005 | 1.00 | ALDH1A1 (0.89) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL19685101 | 1.00 | — | — | |
| SCHEMBL20193393 | 1.00 | ALDH1A1 (0.89) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL18897676 | 1.00 | ALDH1A1 (0.89) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL27743 | 1.00 | — | — | |
| SCHEMBL19072068 | 1.00 | ALDH1A1 (0.89) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL21841873 | 1.00 | ALDH1A1 (0.89) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL16878797 | 0.95 | ALDH1A1 (0.80) | ALDH1A1THRBMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847119-B2 | Drug conjugates | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080139815-A1 | DRUG CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-12 | — | — | US | disclosed |
| US-7282590-B2 | Selectively target tumor cells with highly potent cytotoxic drugs at a drug release rate that is effective for the destruction and/or inhibition of tumor cells | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1718335-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | disclosed |
| WO-2005079398-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232928-A1 | Drug conjugates | RXRB, NR0B1, RXRA | ALDH1A1 399/4885THRB 468/4885MEN1 3583/4885 |
| US-20080139815-A1 | DRUG CONJUGATES | RXRB, NR0B1, RXRA | ALDH1A1 414/4885THRB 477/4885MEN1 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.